#USA #Stamford #Caristo Diagnostics #Abcentra #Orticumab

Caristo Applauds Abcentra's First Patient Dosing in FORTIFY Trial

In a significant milestone for cardiovascular research, Caristo Diagnostics has congratulated Abcentra for successfully dosing the first patient in their Phase 2b clinical trial known as FORTIFY. This trial is designed to evaluate the safety and efficacy of orticumab, a revolutionary monoclonal antibody targeted towards cardiovascular inflammation.

The FORTIFY trial, which stands for Focused Orticumab Research for Treating Inflammation in Coronary Arteries, involves a rigorous, multi-center approach that is both randomized and placebo-controlled. It aims to assess orticumab's ability to reduce local coronary inflammation in patients who have experienced type 1 myocardial infarctions. With a total of 240 adult participants enrolled at various sites across the U.S. and Europe, this trial promises to be a benchmark in the advancement of treatments aimed at minimizing heart attack risks.

Caristo plays a vital role in this clinical trial as its worldwide imaging core lab. Their innovative technologies, like CaRi-Heart and the FAI-Score, are instrumental in verifying coronary inflammation through advanced imaging techniques. By measuring parameters like the Fat Attenuation Index (FAI) score, Caristo aids in patient selection and monitoring throughout the study.

Abcentra's CEO, Christopher Farina, emphasized the significance of Caristo's capabilities, stating that their cutting-edge imaging technology allows for precise measurements of coronary inflammation, crucial for confirming the efficacy of orticumab in treating the root causes of heart disease. Moreover, the trial's design focuses on identifying eligible candidates based on elevated coronary inflammation, which is an independent predictor of future cardiovascular events.

The responsibilities of Caristo within the FORTIFY trial encompass not only certifying and training clinical sites for high-quality coronary computed tomographic angiography but also conducting comprehensive analyses of all patients at the baseline and following their randomized treatments.

Frank Cheng, CEO of Caristo Diagnostics, remarked on the growing trend of pharma and biotech firms leaning on their expertise to help select trial candidates effectively. He expressed pride in the partnership with Abcentra, highlighting the importance of understanding how coronary plaque and inflammation — which are critical indicators of heart attack risks — respond to new therapies.

Caristo Diagnostics is staunchly focused on transforming cardiovascular care through early detection and personalized treatment options. Originating as a spinout from the University of Oxford, they leverage AI-powered solutions to uncover heart disease risks before they manifest symptomatically.

In essence, this partnership and the FORTIFY trial represent a forward leap in the fight against cardiovascular diseases, aiming not just to treat but to preemptively address one of the leading causes of mortality worldwide. With Abcentra's commitment to innovative therapeutics and Caristo's pioneering imaging technologies, the future of cardiovascular care looks optimistic. For more information about their groundbreaking work, you can visit their respective websites at caristo.com and abcentra.com.

Together, they are shaping a new era in cardiovascular treatments — one that seeks to offer hope and effective solutions to those at risk of heart disease.